A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

ClinicalTrials.gov ID: NCT01258907

Public ClinicalTrials.gov record NCT01258907. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Double Blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER - Goal of Oxidized Ldl and Activated Macrophage Inhibition by Exposure to a Recombinant Antibody)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a Phase II (proof-of-activity), double-blind, placebo-controlled, randomized, multicenter study of MLDL1278A (also known as BI-204) involving patients on standard-of-care therapy for atherosclerotic cardiovascular disease with evidence of vascular inflammation, as quantified by FDG-PET/CT.

Study identification

NCT ID: NCT01258907
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 147 participants

Conditions and interventions

Conditions

Atherosclerosis

Interventions

Drug

Eligibility (public fields only)

Age range: 35 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 28, 2010
Primary completion: Jun 30, 2012
Completion: Not listed
Last update posted: Nov 1, 2016

Started 2010

United States locations

U.S. sites: 22
U.S. states: 14
U.S. cities: 18

Facility	City	State	ZIP	Site status
Not listed	Torrance	California	90502	—
Not listed	Colorado Springs	Colorado	80904	—
Not listed	Washington D.C.	District of Columbia	20010	—
Not listed	Gainesville	Florida	32605	—
Not listed	Jacksonville	Florida	32216	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Boston	Massachusetts	02114	—
Not listed	Haverhill	Massachusetts	01830	—
Not listed	Royal Oak	Michigan	48073	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Saint Paul	Minnesota	55102	—
Not listed	Kansas City	Missouri	64111	—
Not listed	Newington	New Hampshire	03801	—
Not listed	New York	New York	10001	—
Not listed	New York	New York	10029	—
Not listed	North Massapequa	New York	11758	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Cincinnati	Ohio	45227	—
Not listed	Portland	Oregon	97225-3411	—
Not listed	Portland	Oregon	97239	—
Not listed	Houston	Texas	77002	—
Not listed	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01258907, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 1, 2016 · Synced Sep 3, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01258907 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →